Safety and Efficacy of Radiofrequency Ablation for Hepatic Metastases from Gastrointestinal XXXX .

@entity1 @entity548 @entity5 @entity674 @entity2213
PURPOSE: To evaluate the safety and efficacy of radiofrequency (RF) ablation for hepatic metastases from @entity674 ( @entity674 ). MATERIALS AND METHODS: Retrospective review of a prospectively maintained database was performed between February 2002 and November 2010 and identified 29 @entity1 with GISTs (18 male; age range, 35-77 y; median age, 61 y) who had undergone ultrasound-guided RF ablation for metastases detected in the liver. All @entity1 had been treated with @entity2213 . Indications for RF ablation were @entity5 progression during medical therapy or the development of drug resistance after @entity5 control. The average number of target lesions per procedure was 2.3 (range, 1-8), and mean lesion diameter was 1.3 cm (range, 0.4-3.6 cm). RESULTS: For 69 lesions among 86 hepatic metastases, RF ablation was successfully performed according to the protocol currently in use. In 17 hepatic metastases in 13 @entity1 , RF ablation was not performed because of poor lesion visibility or possible thermal damage to adjacent organs. Major complications included @entity548 at the ablation site in one @entity1 and peritoneal seeding near the ablation tract in another @entity1 . Technical effectiveness was achieved for 66 of 69 lesions (95.6%). The median follow-up period was 33.1 months (range, 12.3-108.6 mo). Four of 66 lesions (6%) showed local recurrence at 3.2-10.5 months. Four @entity1 died of disease progression. The median overall survival period was 90.2 months (range, 12.3-108.6 mo). CONCLUSIONS: RF ablation appears to be a safe and effective treatment for hepatic metastases of @entity674 when medical therapy fails.
